Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

View All Documentation

44066

Sigma-Aldrich

D-Sphingosine

≥98.0% (TLC)

Sinonimo/i:

Sphingosine, (2S,3R,4E)-2-Amino-4-octadecene-1,3-diol, 4-Sphingenine, trans-D-erythro-2-Amino-4-octadecene-1,3-diol

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C18H37NO2
Numero CAS:
123-78-4
Peso molecolare:
299.49
Beilstein:
1727294
Numero CE:
204-651-3
Numero MDL:
MFCD00036751
Codice UNSPSC:
12352211
ID PubChem:
329756448
NACRES:
NA.85

Saggio

≥98.0% (TLC)

Forma fisica

powder

Tipo di lipide

sphingolipids

Temperatura di conservazione

−20°C

Stringa SMILE

OC[C@@](N)([H])[C@]([H])(O)/C=C/CCCCCCCCCCCCC

InChI

1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h14-15,17-18,20-21H,2-13,16,19H2,1H3/b15-14+/t17-,18+/m0/s1
WWUZIQQURGPMPG-KRWOKUGFSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Azioni biochim/fisiol

A constituent of cell membranes. Precursor of ceramide. Selective inhibitor of protein kinase C, but does not inhibit protein kinase A or myosin light chain kinase. Inhibitor of calmodulin-dependent enzymes.

Confezionamento

Bottomless glass bottle. Contents are inside inserted fused cone.

Indicazioni di pericolo

H413

Consigli di prudenza

P273 - P501

Classi di pericolo

Aquatic Chronic 4

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 4

1 of 4

Ceramide (Brain) Ceramide (Brain, Porcine), powder

Avanti

860052P

Ceramide (Brain)

Sphingosine (d17:1) Avanti Research™ - A Croda Brand LM2000, ethanol solution

Avanti

LM2000

Sphingosine (d17:1)

Sphingosine kinase 1 Active human recombinant, expressed in baculovirus, ≥80% (SDS-PAGE)

Sigma-Aldrich

SRP0283

Sphingosine kinase 1 Active human

Sphingosine (d17:1) Avanti Research™ - A Croda Brand 860640P, powder

Avanti

860640P

Sphingosine (d17:1)

Meret E Ricklin et al.
Neurology, 81(2), 174-181 (2013-05-24)
To study the immune response against varicella-zoster virus (VZV) in patients with multiple sclerosis before and during fingolimod therapy. The VZV-specific immune response was studied using interferon (IFN)-γ enzyme-linked immunosorbent spot assay, proliferation assays, and upregulation of T-cell activation markers
Tim Ting Chiu et al.
The Journal of biological chemistry, 288(24), 17520-17531 (2013-05-04)
Insulin activates a cascade of signaling molecules, including Rac-1, Akt, and AS160, to promote the net gain of glucose transporter 4 (GLUT4) at the plasma membrane of muscle cells. Interestingly, constitutively active Rac-1 expression results in a hormone-independent increase in
David Henault et al.
Neurology, 81(20), 1768-1772 (2013-10-18)
To determine the range of fluctuation in total lymphocyte counts (TLCs) in peripheral blood over a 4- to 7-year period in patients with MS receiving fingolimod (FTY720) and the relation between TLCs and T-cell subsets (CD4+, CD8+, CCR7+/-) that are
Vilija G Jokubaitis et al.
Neurology, 82(14), 1204-1211 (2014-03-13)
To determine early risk of relapse after switch from natalizumab to fingolimod; to compare the switch experience to that in patients switching from interferon-β/glatiramer acetate (IFN-β/GA) and those previously treatment naive; and to determine predictors of time to first relapse
Paolo Neviani et al.
The Journal of clinical investigation, 123(10), 4144-4157 (2013-09-04)
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) depends on the requirement for BCR-ABL1 kinase activity in CML progenitors. However, CML quiescent HSCs are TKI resistant and represent a BCR-ABL1 kinase-independent disease reservoir. Here we
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.